Clinical Trial Update: Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab with tremelimumab, with or without radiation therapy, in metastatic colorectal cancer and metastatic non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-25